Because the overall average of every verified analyst target fell below the 10% threshold above the current price, the $220 central target used here is calculated from only the targets above the latest close — not a headline consensus figure. For context, the full set of targets reviewed averages about $213, with a range from roughly $175 to $240.
Recent, firm-attributed targets illustrate how views diverge. Stifel raised its target to $232 (Nov. 3, 2026), while Goldman Sachs reiterated a Buy with a $222 target and Barclays maintained Buy at $225 (both Oct. 28, 2026). Argus Research lifted its target to $220 (Oct. 26, 2026), Morgan Stanley stood at $215, and Bank of America edged its target to $211 (Nov. 5, 2026). More cautious houses sit at the lower end: UBS holds a $201 target (Hold) and Bernstein maintains a $175 target (Hold).
Most ratings cluster around Buy, but the wide $175-to-$240 spread reflects genuine debate over how richly to value a company whose growth now depends heavily on reduced-risk products rather than traditional cigarettes.
The shares closed at $197.88 on Nov. 6, 2026, within a 52-week range of $146.35 to $214.35. Reaching $220 would require a gain of about 11%, a modest single-step move for a large-cap staple that has returned roughly 37% over the past year. PM trades near 29 times trailing EPS (earnings per share), a premium to its long-term historical multiple that raises the bar for further re-rating.
The path to $220 would likely depend less on a valuation expansion and more on continued earnings delivery: analysts model adjusted EPS rising from roughly $8.40 in fiscal 2026 toward $9.17 in 2027. Sustained smoke-free volume growth and stable combustible margins would be the clearest fundamental drivers.
Philip Morris International is in the middle of a strategic shift toward smoke-free products such as IQOS heated tobacco and ZYN nicotine pouches, which now reach dozens of markets and tens of millions of users. Third-quarter 2026 revenue of about $11.44 billion and EPS of $2.20 exceeded consensus expectations, and the company has demonstrated consistent pricing power and margin discipline.
Income investors also provide a support base: the forward dividend has grown, with a current annualized payout near $6.40 per share (a yield of roughly 3.2%). Defensive cash generation, a consumer staples profile with a low beta, and the potential for a U.S. IQOS ILUMA launch pending FDA (Food and Drug Administration) authorization are recurring bullish themes in analyst notes.
Regulation is the dominant risk. Nicotine policy, flavor restrictions, and FDA decisions on modified-risk products can shift the growth outlook quickly, and the U.S. ZYN business remains a focal point of uncertainty. A premium valuation also leaves little margin for error — if earnings momentum softens, the multiple could compress even as profits grow.
Concentration is another concern: the bull case hinges on the smoke-free transition continuing to offset cigarette volume declines in an industry where overall tobacco consumption is structurally flat to down. Any guidance trim or slower smoke-free adoption would likely pressure the shares and make $220 harder to reach.
The 52-week high of $214.35 stands as the nearest major resistance zone, with the psychological $220 level just above it. A durable support band has formed near $175, aligning with the low end of the analyst range and with prior consolidation. The stock's long-term uptrend remains intact after the strong three- and five-year returns, but the recent pullback from the October highs suggests buyers are awaiting fresh catalysts before pushing through prior peaks.
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms apply different frameworks. Investors weighing the path toward $220 should watch quarterly earnings and guidance, smoke-free shipment and user metrics, any FDA decisions on IQOS or ZYN, dividend announcements, and analyst revisions. Macroeconomic factors such as interest-rate moves and currency swings also matter, given PM's broad international footprint.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, track positions, and identify changing trends more efficiently than manual scanning allows. For investors following PM or similar names, these signals offer an additional, data-driven lens to complement fundamental research and analyst targets.
Can PM reach $220? The target is reachable in principle, representing only about an 11% move and sitting just above the 52-week high. It is supported by strong smoke-free momentum, reliable earnings beats, dividend growth, and a generally bullish analyst posture. Yet it is not guaranteed: the wide $175-to-$240 range of analyst targets, the premium valuation, and persistent regulatory and concentration risks all argue for caution. The most constructive path requires continued smoke-free volume growth and stable margins, while the clearest downside would come from a guidance cut or an unfavorable regulatory development.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PM has been loosely correlated with BTI. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PM jumps, then BTI could also see price increases.